Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice

Clinical Cancer Research

Volumn 7, Issue 11 SUPPL., 2001, Pages

  Xiang, Rong ^a   Silletti, Steve ^b   Lode, Holger N ^c   Dolman, Carrie S ^a   Ruehlmann, J Michael ^a   Niethammer, Andreas G ^a   Pertl, Ursula ^a   Gillies, Stephen D ^d   Primus, F James ^e   Reisfeld, Ralph A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b Whittier Institute for Diabetes   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Lexigen Pharmaceuticals Corp   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULE; CYTOKINE; DNA VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYBRID PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; TUMOR ANTIGEN; TUMOR ASSOCIATED ANTIGEN GA733; TUMOR-ASSOCIATED ANTIGEN GA733;

ANIMAL; ARTICLE; C57BL MOUSE; CELL CULTURE; COLON TUMOR; GENETIC TRANSFECTION; HUMAN; IMMUNOBLOTTING; METABOLISM; MOUSE; PLASMID; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOEMBRYONIC ANTIGEN; CELL ADHESION MOLECULES; COLONIC NEOPLASMS; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOBLOTTING; INTERCELLULAR ADHESION MOLECULE-1; INTERFERON TYPE II; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLASMIDS; RECOMBINANT FUSION PROTEINS; TRANSFECTION; TUMOR CELLS, CULTURED; UP-REGULATION; VACCINES, DNA;

EID: 0035293323     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Boon, T., Cerottini, J-C., Van den Eynde, B., van der Bruggen, P., and Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol., 12: 337-365, 1994.
2. Houghton, A. N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med., 180: 1-4, 1994.
3. Gilboa, E., Nair, S. K., and Lyerly, H. K. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother., 46: 82-87, 1998.
4. Schlom, J. Carcinoembryonic antigen (CEA) peptides and vaccines for carcinoma. In: M. Kast (ed.), Peptide-based Cancer Vaccines, in press Austin, TX: Landes Bioscience, 2000.
5. Shively, J. E., and Beatty, J. D. CEA-related antigens: molecular biology and clinical significance. Crit. Rev. Oncol. Hematol., 2: 355-399, 1985.
6. Thompson, J., and Zimmermann, W. The carcinoembryonic antigen gene family: structure, expression and evolution. Tumor Biol., 9: 63-83, 1988.
7. Von Kleist, S., Migule, I., and Halla, B. Possible function of CEA as cell-contact inhibitory molecule. Anticancer Res., 15: 1889-1894, 1995.
8. Sharkey, R. M., Goldenberg, D. M., Goldenberg, H., Lee, R. E., Balance, C., Powlyk, D., Varga, D., and Hansen, H. J. Murine monoclonal antibodies against carcinoembryonic antigen: pharmacokinetic and targeting properties in humans. Cancer Res., 50: 2823-2831, 1990.
9. 90yttrium-radiolabeled anti-carcinoembryonic antigen chimeric T84.66 in a Phase I radioimmunotherapy trial. Cancer Res., 55: 5929s-5934s, 1995.
10. Kantor, J., Irvine, K., Abrams, S., Kaufmann, H., DiPietro, J., and Schlom, J. Anti-tumor activity and immune responses induced by a recombinant vaccinia-carcinoembryonic antigen (CEA) vaccine. J. Natl. Cancer Inst., 84: 1084-1091, 1992.
11. Schrewe, H., Thompson, J., Bona, M., Hefta, L. J. F., Maruya, A., Hassauer, M., Shively, J. E., von Kleist, S., and Zimmermann, W. Cloning of the complete gene for carcinoembryonic antigen: analysis of its promoter indicates a region conveying cell type-specific expression. Mol. Cell. Biol., 10: 2738-2748, 1990.
12. Clarke, P., Mann, J., Simpson, J. F., Ricard-Dickson, K. J., and Primus, F. J. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res., 58: 1469-1477, 1998.
13. Mizobata, S., Tompkins, K., Simpson, J. F., Shyr, Y., and Primus, F. J. Induction of cytotoxic T cells and their anti-tumor activity in mice transgenic for carcinoembryonic antigen. Cancer Immunol. Immunother., in press, 2000.
14. Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., and Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst., 87: 982-990, 1995.
15. Kawashima, I., Hudson, S. J., Tsai, V., Southwood, S., Takesako, K., Appella, E., Sette, A., and Celis, E. The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. Hum. Immunol., 59: 1-14, 1998.
16. Lo Gerfo, P., Herter, F. P., and Bennet, S. J. Absence of circulating antibodies to carcinoembryonic antigen in patients with gastrointestinal malignancies. Int. J. Cancer, 9: 344-348, 1972.
17. Matzku, S., Zöller, M., Schulz, U., Dietze, W., Barth, H. O., Saeger, H-D., and Price, M. R. Lack of correlation between carcinoembryonic antigen content of tumor extracts and leukocyte migration reactivity of tumor patients. J. Natl. Cancer Inst., 64: 1345-1348, 1980.
18. McLaughlin, J. P., Schlom, J., Kantor, J. A., and Greiner, J. W. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2. Cancer Res., 56: 2361-2367, 1996.
19. Kass, E., Schlom, J., Thompson, J., Guadagni, F., Graziano, P., and Greiner, J. W. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice by immunizing with a recombinant vaccinia virus. Cancer Res., 59: 676-683, 1999.
20. Hodge, J. W., Sabzevari, H., Gómez-Yatal, A., Gritz, L., Lorenz, M. G. O., and Schlom, J. A triad of co-stimulatory molecules synergizes to amplify T cell activation. Cancer Res., 59: 5800-5807, 1999.
21. Marshall, J. L., Hawkins, M. J., Tsung, K. Y., Richmond, E., Pedicano, J. E., Zhu, M. Z., and Schlom, T. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol., 17: 332-337, 1999.
22. Gillies, S. D., Lan, Y., Wesolowski, K. S., Qian, X., Reisfeld, R. A., Holden, S., Super, M., and Lo, K-M. Antibody-IL12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J. Immunol., 160: 6195-6203, 1998.
23. Wagner, C., Clark, B. R., Rickard, K. J., and Shively, J. E. Monoclonal antibodies for carcinoembryonic antigen and related antigens as a model system: determining of affinities and specificities of monoclonal antibodies by using biotin-labeled antibodies and avidin as precipitating agent in a solution phase immunoassay. J. Immunol., 130: 2302-2307, 1983.
24. Darji, A., Guzmán, G. A., Gerstel, B., Wachholz, P., Timmis, K. N., Wehland, T., Chakraborty, E., and Weiss, S. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell, 91: 765-775, 1997.
25. Matzinger, P. Tolerance, danger and the extended family. Annu. Rev. Immunol., 12: 991-1045, 1994.
26. Kaufmann, S. H. Immunity of intracellular bacteria. Annu. Rev. Immunol., 11: 129-163, 1993.
27. Krieg, A. M., Yi, A-K., Schorr, J., and Davis, H. L. The role of CpG dinucleotides in DNA vaccines. Trends Microbiol., 6: 23-27, 1998.
28. Dustin, M. L., and Springer, T. A. The role of lymphocyte adhesion receptors in transient interactions and cell locomotion. Annu. Rev. Immunol., 9: 27-66, 1993.
29. Hogg, N., and Landis, R. C. Adhesion molecules in cell interactions. Curr. Opin. Immunol., 5: 383-390, 1993.
30. Dustin, M. L., and Springer, T. A. T cell receptor crosslinking transiently stimulates adhesiveness through LFA-1. Nature (Lond.), 341: 619-624, 1989.
31. Linsley, P. S., Brady, W., Grosmaire, L., Aruffo, A., Damle, N. K., and Ledbetter, J. A. Binding of the B cell activation B7 to CD28 co-stimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med., 173: 721-730, 1991.
32. Fraser, J. D., Irving, B. A., Grabtee, G. R., and Weiss, A. Regulation of interleukin-2 gene enhancer activity by the T cell accessory molecule CD28. Science (Washington DC), 251: 313-316, 1991.
33. Maass, G., Schmidt, W., Berger, M., Schilcher, F., Koszik, F., Schneeberger, A., Stingl, G., Birnstiel, M. L., and Schweighoffer, T. Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination. Proc. Natl. Acad. Sci. USA, 95: 5540-5544, 1995.
34. + T cell help-mediated by CD40/CD40L interaction. J. Clin. Investig., 105: 1623-1630, 2000.
35. Xiang, R., Lode, H. N., Dolman, C. S., Dreier, T., Varki, N. M., Qian, X., Lo, K-M., Lan, Y., Super, M., Gillies, S. D., and Reisfeld, R. A. Elimination of established murine colon carcinoma metastases by antibody-interleukin-2 fusion protein therapy. Cancer Res., 57: 4948-4955, 1997.
36. Xiang, R., Lode, H. N., Dreier, T., Gillies, S. D., and Reisfeld, R. A. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res., 58: 3918-3925, 1998.